Authors : P. N. Prakash; V. Divya; S. Hemalatha; P. Karthikeyan; M. Nekitha; S. Rachana

Volume/Issue : Volume 11 - 2026, Issue 3 - March

Google Scholar : https://tinyurl.com/ytcxcbhe

Scribd : https://tinyurl.com/3r37yem8

DOI : https://doi.org/10.38124/ijisrt/26mar808

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Frontotemporal dementia (FTD) is a progressive neurodegenerative disorder characterized by behavioral alterations, language impairment, and cognitive decline resulting from degeneration of the frontal and temporal lobes of the brain. The disease involves multiple pathological mechanisms, including oxidative stress, neuroinflammation, abnormal protein accumulation, and neuronal loss. Despite advancements in understanding its pathology, effective disease-modifying therapies for FTD remain limited. Pergularia daemia, a medicinal climbing plant widely used in traditional systems of medicine, is known to possess a wide range of bioactive phytochemicals such as flavonoids, alkaloids, terpenoids, tannins, and glycosides. Key constituents including quercetin, kaempferol, β-sitosterol, and lupeol exhibit notable antioxidant and anti-inflammatory activities. These compounds may contribute to neuroprotection by reducing oxidative damage, modulating inflammatory responses, and preventing neuronal degeneration. Thus, Pergularia daemia demonstrates promising potential as a natural source for developing neuroprotective agents in the management of frontotemporal dementia. However, further in vitro, in vivo, and clinical investigations are necessary to confirm its therapeutic efficacy and safety.

References :

1. Peter A Ljubenkov, Bruce L Miller. Frontotemporal dementia: Clinical features and diagnosis. 2016 Oct;14(4): 448-464. [Pub Med].
2. Banks S, Weintraub S. Self-awareness and selffmonitoring of cognitive and behavioral deficits in behavioral variant frontotemporal dementia, primary progressive aphasia and probable Alzheimer's disease. Brain Cogn. 2008;67(1):58-68.
3. Richard M Tsai, Adam L Boxer, Frontotemporal dementia: treatment.2014 Nov;16(11): 319. [Pub Med].
4. Olney NT, Spina S, Miller BL. Frontotemporal Dementia. Neurol Clin. 2017 May;35(2):339-374. [PMC free article] [PubMed]
5. Bott NT, Radke A, Stephens ML, Kramer JH. Frontotemporal dementia: diagnosis, deficits and management. Neurodegener Dis Manag. 2014;4(6):439-54. [PMC free article] [PubMed]
6. Shpilyukova YA, Fedotova EY, Illarioshkin SN. [Genetic Diversity in Frontotemporal Dementia]. Mol Biol (Mosk). 2020 Jan-Feb;54(1):17-28. [PubMed]
7. Bang, J., Spina, S., & Miller, B. L. (2015). Frontotemporal dementia. The Lancet, 386(10004), 1672–1682.
8. Neumann, M., Sampathu, D. M., Kwong, L. K., et al. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science, 314(5796), 130–133.
9. Onyike, C. U., & Diehl-Schmid, J. (2013). The epidemiology of frontotemporal dementia. International Review of Psychiatry, 25(2), 130–137.
10. Butterfield, D. A., & Halliwell, B. (2019). Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nature Reviews Neuroscience, 20, 148–160. (Often cited for oxidative stress mechanisms in neurodegenerative diseases including FTD.)
11. Rascovsky, K., Hodges, J. R., Knopman, D., et al. (2011). Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain, 134(9), 2456–2477.
12. Goedert, M., & Spillantini , M. G. (2006). A century of Alzheimer’s disease. Science, 314(5800), 777–781.(Discusses tau protein aggregation relevant to FTD pathology.)
13. Lin, M. T., & Beal, M. F. (2006). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature, 443, 787–795.
14. Vauzour, D., Vafeiadou, K., Rodriguez-Mateos, A., Rendeiro, C., & Spencer, J. P. (2008). The neuroprotective potential of flavonoids: a multiplicity of effects. Genes & Nutrition, 3(3-4), 115–126.
15. Bang, J., Spina, S., & Miller, B. L. (2015). Frontotemporal dementia. The Lancet, 386(10004), 1672–1682.
16. Rascovsky, K., Hodges, J. R., Knopman, D., et al. (2011). Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain, 134(9), 2456–2477.
17. Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., et al. (2011).Classification of primary progressive aphasia and its variants. Neurology, 76(11), 1006–1014.
18. Onyike, C. U., & Diehl-Schmid, J. (2013).The epidemiology of frontotemporal dementia. International Review of Psychiatry, 25(2), 130–137.
19. Roberson, E. D., & Miller, B. L. (2010).Frontotemporal dementia: epidemiology, pathophysiology, diagnosis and management. Drugs, 70(18), 2453–2477.
20. Piguet, O., Hornberger, M., Mioshi, E., & Hodges, J. R. (2011).Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management. The Lancet Neurology, 10(2), 162–172.
21. Suresh Kumar, S. V., Mishra, S. H., & Rao, C. V. (2006).Phytochemical and pharmacological studies on Pergularia daemia. Pharmacognosy Magazine, 2(6), 97–100.
22. Gupta, R., Sharma, A. K., & Dobhal, M. P. (2010).Antioxidant activity of Pergularia daemia extracts .International Journal of Pharmaceutical Sciences Review and Research, 5(2), 45–49.
23. Senthilkumar, K. L., & Venkatesalu, V. (2012). Phytochemical analysis and antimicrobial activity of Pergularia daemia.Asian Pacific Journal of Tropical Biomedicine, 2(3), S1151–S1155.
24. Kirtikar, K. R., & Basu, B. D. (2005). Indian Medicinal Plants (Vol. 3). Dehradun: International Book Distributors. (Describes flavonoids, tannins, and traditional medicinal uses of the plant.)
25. Nadkarni, K. M. (2009). Indian Materia Medica (Vol. 2). Mumbai: Popular Prakashan.
26. Kokate, C. K., Purohit, A. P., & Gokhale, S. B. (2010).Pharmacognosy. Pune: Nirali Prakashan
27. Patel DK, Kumar R, Laloo D, Hemalatha S. Pharmacognostical and phytochemical evaluation of Pergularia daemia. International Journal of Pharmaceutical Sciences Review and Research. 2013;20(1):178-184.
28. Kumar S, Kumar V, Prakash O. A review on Pergularia daemia (Forssk.) Chiov. International Journal of Pharmaceutical Sciences and Research. 2013;4(2):450-457.
29. Senthilkumar RP, Bhuvaneshwari V. Phytochemical screening and antioxidant activity of Pergularia daemia. Asian Pacific Journal of Tropical Disease. 2015.
30. Natarajan D, Britto SJ. Pharmacological and phytochemical studies on Pergularia daemia. Journal of Ethnopharmacology. 2007.
31. Harborne JB. Phytochemical Methods: A Guide to Modern Techniques of Plant Analysis. 3rd ed. Chapman & Hall; 1998.
32. Jain, S., Pancholi, B., & Jain, R. (2012). Studies on antimicrobial and antioxidant potentials of Pergularia daemia (Forsk.) Chiov. Asian Journal of Chemistry, 24(8), 3513-3516.
33. Dosumu, O. O., et al. (2019). Phytochemical composition and antioxidant and antimicrobial activities of Pergularia daemia. Journal of Medicinal Plants for Economic Development.
34. Akhil, G. H., Bibu, J. K., Sujarani, S., Shynu, M., & Usha, P. T. A. (2019). Phytochemical analysis and in vitro antioxidant activity of methanol extract of leaves of Pergularia daemia. Journal of Pharmacognosy and Phytochemistry, 8(6), 2106-2111.
35. Ananth, D. A., et al. (2016). Flavonoid-rich extract of Pergularia daemia and its anti-inflammatory activity. Biomedicine & Pharmacotherapy.
36. Solleti, S. K., et al. (2008). Hepatoprotective effect of Pergularia daemia ethanol extract. Indian Journal of Pharmacology.37. Review article: “Active status on phytochemistry and pharmacology of Pergularia daemia (Trellis-vine)” Clinical Phytoscience, 2021.